English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine BioTech
Prenetics收购行动基因 首次公开招股后首宗并购交易 势扩大癌症基因组学之份额
Dec 16, 2022 19:59 HKT
Prenetics收購行動基因 首次公開招股後首宗並購交易 勢擴大癌症基因組學之份額
Dec 16, 2022 19:58 HKT
Prenetics Acquires ACT Genomics; First M&A Deal since IPO, Set to Expand Footprint in Cancer Genomics
Dec 16, 2022 19:57 HKT
数据显示 50% 的新试验位于亚太地区
Dec 16, 2022 07:00 HKT
數據顯示 50% 的新試驗位於亞太地區
Dec 16, 2022 07:00 HKT
자료 보고, 새로운 임상 시험 중 50%의 시험 장소가 아시아 태평양 지역에 위치
Dec 16, 2022 07:00 HKT
Data Shows 50% of New Trials Have Sites in Asia Pacific
Dec 15, 2022 10:00 HKT
Sirnaomics宣布STP705用于治疗成人原位鳞状细胞皮肤癌的IIb期临床试验获得积极中期数据
Dec 14, 2022 23:17 HKT
Sirnaomics宣佈STP705用於治療成人原位鱗狀細胞皮膚癌的IIb期臨床試驗獲得積極中期數據
Dec 14, 2022 23:16 HKT
Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ
Dec 14, 2022 23:15 HKT
Preventing Strokes and Heart Attacks Doesn't Have to Come with the Risk of Life-threatening Bleeding
Dec 14, 2022 21:45 HKT
Sirnaomics执行董事戴晓畅博士将于2022年度香港国际生物科技展上发表主题演讲
Dec 14, 2022 11:58 HKT
Sirnaomics執行董事戴曉暢博士將於2022年度香港國際生物科技展上發表主題演講
Dec 14, 2022 11:57 HKT
Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
Dec 14, 2022 11:56 HKT
Polymer protection for vaccines and drugs
Dec 09, 2022 23:00 HKT
Led by Legend Capital, GS Biotech Completes Nearly CNY100 million Pre-A Round Financing
Dec 09, 2022 19:27 HKT
Novotech 荣获 2022 年亚太地区 CRO 临床试验最佳实践奖
Dec 07, 2022 06:00 HKT
Novotech 榮獲 2022 年亞太地區 CRO 臨床試驗最佳實踐獎
Dec 07, 2022 06:00 HKT
노보텍, 임상 시험 모범 사례로 2022년 아시아 태평양 CRO 상 수상
Dec 07, 2022 06:00 HKT
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
Dec 06, 2022 14:00 HKT
<< Previous  Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: